Esketamine: Postmarketing Safety Concerns
Psychopharmacology and Psychiatry Updates - A podcast by Psychopharmacology Institute
Categorie:
How risky is esketamine? In this episode, we examine the safety of esketamine using postmarketing data that have been reported since the drug was approved and released. Faculty: Jim Phelps, M.D. Hosts: Jessica Diaz, M.D.; Flavio Guzman, M.D. Learn more about our memberships here Earn 0.5 CMEs: Quick Take Vol. 27 Postmarketing Safety Concerns With Esketamine: A Disproportionality Analysis of Spontaneous Reports Submitted to the FDA Adverse Event Reporting System
